Emergent Biosolutions (EBS) Expected to Announce Earnings on Monday

Emergent Biosolutions (NYSE:EBS) is expected to be releasing its Q3 2026 results after the market closes on Monday, November 2nd. Analysts expect the company to announce earnings of ($0.37) per share and revenue of $123.22 million for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Monday, November 2, 2026 at 5:00 PM ET.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.68. Emergent Biosolutions had a negative net margin of 22.95% and a positive return on equity of 16.35%. The firm had revenue of $234.30 million during the quarter, compared to analysts’ expectations of $177.50 million. On average, analysts expect Emergent Biosolutions to post $0.13 EPS for the current fiscal year and $0.74 EPS for the next fiscal year.

Emergent Biosolutions Stock Performance

NYSE EBS opened at $6.24 on Monday. The company has a debt-to-equity ratio of 1.70, a current ratio of 5.42 and a quick ratio of 2.95. Emergent Biosolutions has a 1 year low of $4.36 and a 1 year high of $14.06. The company has a market capitalization of $320.08 million, a PE ratio of -1.76 and a beta of 2.28. The company has a fifty day moving average of $6.29 and a two-hundred day moving average of $7.34.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Zacks Research upgraded Emergent Biosolutions to a “hold” rating in a research report on Tuesday, August 11th. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Emergent Biosolutions in a research report on Wednesday, September 9th. JPMorgan Chase & Co. began coverage on Emergent Biosolutions in a research report on Friday, August 21st. They issued an “underweight” rating for the company. Finally, Weiss Ratings upgraded Emergent Biosolutions from a “sell (d-)” rating to a “sell (d)” rating in a research note on Friday, August 21st. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $10.00.

Insider Activity at Emergent Biosolutions

In other news, Director Donald Degolyer sold 17,800 shares of Emergent Biosolutions stock in a transaction on Wednesday, October 7th. The shares were sold at an average price of $7.09, for a total value of $126,202.00. Following the transaction, the director directly owned 111,921 shares of the company’s stock, valued at $793,519.89. The trade was a 13.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.00% of the stock is owned by insiders.

About Emergent Biosolutions

Emergent BioSolutions Inc is a life sciences company that develops, manufactures and supplies medical countermeasures for public health threats. Its portfolio has included products for protection against anthrax and smallpox, as well as treatments and emergency medicines used in overdose response and other acute-care settings.

The company has also provided contract development and manufacturing services for pharmaceutical and biotechnology companies, supporting activities such as drug substance and product manufacturing, packaging and related commercialization services.